FDA Approves Investigational New Drug Application for Adventrx Cancer Drug
SAN DIEGO (AP) -- Adventrx Pharmaceuticals Inc. said Tuesday the Food and Drug Administration accepted its investigational new drug application for a potential cancer drug.
The drug maker will conduct trials to establish that its drug, ANX-530, works the same as Navelbine, an anti-cancer agent approved to fight non-small cell lung cancer.
A 28-person clinical trial is expected to begin in January.
Adventrx expects to file a new drug application by the end of 2007, potentially making ANX-530 the company's first commercial oncology product.
Shares closed Friday's American Stock Exchange session at $2.64, and rose 11 cents, or 4.2 percent, to $2.75 in pre-market electronic trading. Over the past year, the stock has ranged between $2.26 and $5.38.
ANX is trading up again today at $2.82, up 18 cents per share.
ANX-530 is the same a Navelbine, which are cell cycle inhibitors. Dividing cells have specific stages of replication. ANX-530 stops cell division at the mitosis stage, M phase. It interacts with a protein called tubulin, which is necessary for chromosome separation and microtubule assembly. ANX-530 belongs to the class of drugs termed vinca alkoloids.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment